[Stock Spotlight] Daewon Pharmaceutical strengthens on phase 3 success of new gastroesophageal reflux drug
Predicted impact: Medium
Phase 3 success for new drug; stock jumped about 16%, commercial size not yet quantified.
Comments
No comments yet. Start the conversation.
Comments are people's own views. Nothing here is financial advice.